A phase II study (TACTI-002) in first-line metastatic non-small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population
Felip, E. Majem, M. Doger, B. Clay, T. D. Carcereny, E. Bondarenko, I. Peguero, J. A. Cobo-Dols, M. Forster, M. Ursol, G.
Felip, E.
Majem, M.
Doger, B.
Clay, T. D.
Carcereny, E.
Bondarenko, I.
Peguero, J. A.
Cobo-Dols, M.
Forster, M.
Ursol, G.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Felip E, Majem M, Doger B, Clay TD, Carcereny E, Bondarenko I, et al. A phase II study (TACTI-002) in first-line metastatic non-small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680302194.